Search research articles
Contact Us
Filters
Showing results (21-30 of 151) with videos related to
Page
of 16
Sort By:
The American Journal of Cardiology
|
April 25, 1986
Effects of chronic administration of agonists and antagonists on the density of beta-adrenergic receptors
K A Neve, P B Molinoff
Molecular Pharmacology
|
December 16, 1997
Constitutive activity of a chimeric D2/D1 dopamine receptor
L B Kozell, K A Neve
Biochemical Pharmacology
|
August 15, 1988
Development and characterization of anti-spiroperidol antibodies
K A Neve, D E Casey
Pharmacology & Therapeutics
|
June 1, 2005
Sensitization of adenylate cyclase by Galpha i/o-coupled receptors
Val J Watts, Kim A Neve
Biochemical Society Transactions
|
February 1, 1995
Four ways of being an agonist: multiple sequence determinants of efficacy at D2 dopamine receptors
K A Neve, B L Wiens
Neuroscience Letters
|
April 20, 1984
The effects of denervation and chronic haloperidol treatment on neostriatal dopamine receptor density are not additive in the rat
K A Neve, J F Marshall
Molecular Pharmacology
|
August 1, 1997
Activation of type II adenylate cyclase by D2 and D4 but not D3 dopamine receptors
V J Watts, K A Neve
Molecular Pharmacology
|
October 1, 1996
Sensitization of endogenous and recombinant adenylate cyclase by activation of D2 dopamine receptors
V J Watts, K A Neve
Molecular Pharmacology
|
August 1, 1986
Turnover of beta 1- and beta 2-adrenergic receptors after down-regulation or irreversible blockade
K A Neve, P B Molinoff
Acta Physiologica (Oxford, England)
|
November 22, 2011
Osteocytes: central conductors of bone biology in normal and pathological conditions
A Neve, A Corrado, F P Cantatore
Page
of 16
Search research articles
Search
Showing results (21-30 of 151) with videos related to
Sort By:
Page
of 16
The American Journal of Cardiology
|
April 25, 1986
Effects of chronic administration of agonists and antagonists on the density of beta-adrenergic receptors
K A Neve, P B Molinoff
Molecular Pharmacology
|
December 16, 1997
Constitutive activity of a chimeric D2/D1 dopamine receptor
L B Kozell, K A Neve
Biochemical Pharmacology
|
August 15, 1988
Development and characterization of anti-spiroperidol antibodies
K A Neve, D E Casey
Pharmacology & Therapeutics
|
June 1, 2005
Sensitization of adenylate cyclase by Galpha i/o-coupled receptors
Val J Watts, Kim A Neve
Biochemical Society Transactions
|
February 1, 1995
Four ways of being an agonist: multiple sequence determinants of efficacy at D2 dopamine receptors
K A Neve, B L Wiens
Neuroscience Letters
|
April 20, 1984
The effects of denervation and chronic haloperidol treatment on neostriatal dopamine receptor density are not additive in the rat
K A Neve, J F Marshall
Molecular Pharmacology
|
August 1, 1997
Activation of type II adenylate cyclase by D2 and D4 but not D3 dopamine receptors
V J Watts, K A Neve
Molecular Pharmacology
|
October 1, 1996
Sensitization of endogenous and recombinant adenylate cyclase by activation of D2 dopamine receptors
V J Watts, K A Neve
Molecular Pharmacology
|
August 1, 1986
Turnover of beta 1- and beta 2-adrenergic receptors after down-regulation or irreversible blockade
K A Neve, P B Molinoff
Acta Physiologica (Oxford, England)
|
November 22, 2011
Osteocytes: central conductors of bone biology in normal and pathological conditions
A Neve, A Corrado, F P Cantatore
Page
of 16